Skip to content

Clinical study of novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus pneumonia (COVID-19)

Clinical study for novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus (COVID-19)

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030002
Enrollment
Unknown
Registered
2020-02-19
Start date
2020-02-15
Completion date
Unknown
Last updated
2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

control group:conventional therapy
Experience group:conventional therapy and Tranilast

Sponsors

The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. The patients who were diagnosed with the common type of NCP (including severe risk factors) and severe cases of new coronavirus pneumonia; 2. Aged 18 to 85 years; 3. IL-1ß elevated (using Elisa method, using the same company kit); 4. Patients or authorized family members volunteered to participate in this study and signed informed consent; Definition of Novel Coronavirus Pneumonia (NCP) clinical cases: 1. Regular patients with NCP (including severe risk factors): patients with dual pulmonary lesions based on common NCP clinical symptoms accompanied by fever or no fever; 2. Critical NCP patient: Refer to the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Fifth Edition)" formulated by the National Health Commission.

Exclusion criteria

Exclusion criteria: 1. Patients who are participating in other drug clinical trials; 2. Pregnant or lactating women; 3. ALT / AST> 5 ULN, neutrophils <0.5, platelets less than 50; 4. Expected life<1 week; 5. Definite diagnosis of asthma-related diseases; 6. Long-term oral anti-rejection or immunomodulatory drugs; 7. Hypersensitivity to tocilizumab or any excipients; 8. Patients with active pulmonary tuberculosis, with definite bacterial and fungal infections.

Design outcomes

Primary

MeasureTime frame
cure rate;

Secondary

MeasureTime frame
mortality;Ventilator utilization;Hospitalization day;

Countries

China

Contacts

Public ContactHongliang He

The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)

44271370@qq.com+86 15956927046

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026